Out of stock
Safety Advices
বাংলা
English
CAUTION
Caution is advised when consuming alcohol with Roferon-A. Please consult your doctor.
CONSULT YOUR DOCTOR
Roferon-A is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
SAFE IF PRESCRIBED
Roferon-A is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
CONSULT YOUR DOCTOR
It is not known whether Roferon-A alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
CAUTION
Roferon-A should be used with caution in patients with kidney disease. Dose adjustment of Roferon-A may be needed. Please consult your doctor.
SAFE IF PRESCRIBED
Roferon-A is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Roferon-A may not be needed in these patients. Please consult your doctor.
Regular monitoring of liver function tests is advised while you are taking this medicine.
Medicine Overview of Roferon-A 3MIU Injection
Introduction
Roferon-A is used in the treatment of follicular lymphoma and hairy cell leukemia. It works by altering cell function/growth and the body's natural defenses (immune system) in many ways. Roferon-A is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It...
... Show moreUses of Roferon-A
- Follicular lymphoma
- Hairy cell leukemia
Side effects of Roferon-A
Common
- Decreased appetite
- Decreased calcium level in blood
- Decreased white blood cell count
- Diarrhea
- Fatigue
- Flu-like symptoms
- Hair loss
- Headache
- Joint pain
- Muscle pain
- Nausea
- Rigors
- Sweating
- Vomiting
How to use Roferon-A
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Roferon-A works
Roferon-A modulates the body's immune system.
What if you forget to take Roferon-A?
If you miss a dose of Roferon-A, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
Brief Description
Indication
Renal cell carcinoma, Chronic hepatitis B, Chronic hepatitis C, Hairy cell leukaemia, AIDS related Kaposi's sarcoma, Chronic myeloid leukaemia, Follicular lymphoma, Cutaneous T-cell lymphoma, Melanoma
Adult Dose
Subcutaneous Renal cell carcinoma Adult: As an adjunct to cytotoxic chemotherapy: In an escalating dose of 3 million units 3 times wkly for 1 wk, then 9 million units 3 times wkly for 1 wk, then 18 million units 3 times wkly thereafter for 3-12 mth. Chronic hepatitis B Adult: 2.5-5 million units/m2 3 times/wk for 4-6 mth. Chronic hepatitis C Adult: 3-4.5 million units 3 times wkly for 6 mth when used with ribavirin. As monotherapy: Initial: 3-6 million units 3 times wkly for 6 mth followed by 3 million units 3 times wkly for an additional 6 mth,...
... Show moreContraindication
Hypersensitivity. Autoimmune hepatitis, hepatic decompensation.
Mode of Action
Interferon alfa-2a has antiviral, antitumour and immunomodulatory activity. It inhibits replication of a wide range of RNA and DNA viruses. It also exerts antiproliferative effects on normal and malignant cells. Interferon alfa-2a suppresses antibody formation through an effect on B-lymphocytes and inhibits onset of delayed hypersensitivity.
Precaution
History of depression (monitor for signs). Perform regular neuropsychiatric monitoring. Seizure disorders and/or compromised CNS function. Preexisting or any history of cardiac disease. Monitor CBC prior to and during therapy. Myelosuppression or concurrent use of myelosuppressive drugs. Hypothyroidism, hyperthyroidism, DM. Perform ophthalmological exam on patients with preexisting ophthalmologic disorders (e.g. diabetic or hypertensive retinopathy). Monitor patients with impaired renal function. Creatinine clearance <50 ml/min. May impair ability to drive or operate machinery. Pregnancy and lactation.
Side Effect
Depressive illness, suicidal behaviour, irritability, insomnia, anxiety. Flu-like symptoms. Headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. GI disturbances. Dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. Inj site reaction, alopecia, rash, dry skin or pruritus. Conjunctivitis, menstrual irregularity, visual disturbances. Coughing, dyspnoea. Myalgia, joint or bone pain, arthritis or polyarthritis. Bone marrow depression.
Potentially Fatal: Marked increase in triglyceride levels, GI haemorrhage, severe infections, pulmonary infiltrates or pulmonary function impairment.
Interaction
Reduces clearance of theophylline. Enhanced myelosuppression with other myelosuppressive drugs (e.g. zidovudine). Drugs metabolised by CYP450 pathway (monitor for changes in pharmacologic or adverse effects of concomitant drug). Increased risk of toxicity of centrally acting drugs. Increased risk of renal failure with interleukin-2.